Loading patent…
AssigneeHuman Genome Sciences, Inc.
InventorsHaodong Li, Steven M. Ruben, Theodora W. Salcedo, Vikram P. Patel, Robert John Benjamin Nibbs, Gerard John Graham
Estimating the term…
The present invention relates to deletion and substitution mutant polypeptides of human chemokine β-7 (Ckβ-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ckβ-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ckβ-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.
An isolated chemokine α-7 C-terminal deletion mutant selected from the group consisting of:
An isolated chemokine β-7 N-terminal and C-terminal deletion mutant selected from the group consisting of:
A method for inhibiting chemokine induced calcium flux in eosinophils in an individual comprising administering to the individual an effective amount of a chemokine β-7 polypeptide selected from the group consisting of:
Dependencies are inferred from the claim text.